Associations - AR positive

AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	leuprolide acetate Sensitive: A2 - Guideline
AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	bicalutamide Sensitive: A2 - Guideline
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria
AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	palbociclib Sensitive: C3 – Early Trials
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: C3 – Early Trials
AR positive AR positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C3 – Early Trials
AR positive AR positive	Prostate Cancer Prostate Cancer	XY123 Sensitive: C4 – Case Studies
AR positive AR positive	Urothelial Cancer Urothelial Cancer	silodosin Resistant: D – Preclinical
AR positive AR positive	Breast Cancer Breast Cancer	FT-6876 Sensitive: D – Preclinical
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	apalutamide Sensitive: D – Preclinical
AR positive AR positive	Prostate Cancer Prostate Cancer	abemaciclib Sensitive: D – Preclinical
AR positive AR positive	Prostate Cancer Prostate Cancer	GT0918 Sensitive: D – Preclinical
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	darolutamide Sensitive: D – Preclinical